Concepedia

Douglas E. Faries

DE

Statistics

Publications

96

Citations

7.4K

H-Index

44

Active since

1993

Affiliations

Eli Lilly (United States)(Current)

Massachusetts General Hospital

Indiana University – Purdue University Indianapolis

Duke Medical Center

University of Nebraska Medical Center

Douglas E. Faries is an author at Eli Lilly (United States) specializing in psychiatry, psychopharmacology, and pharmacotherapy.

ORCID

Publications per year

1993–2025

96

Publications

96

Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response Study

David Michelson, Douglas E. Faries, Joachim Wernicke et al. · PEDIATRICS · 2001 · 669 citations

, , +17

Medication Adherence and Long-Term Functional Outcomes in the Treatment of Schizophrenia in Usual Care

Haya Ascher‐Svanum, Douglas E. Faries, Baojin Zhu et al. · The Journal of Clinical Psychiatry · 2006 · 488 citations

, , +17

Results From 2 Proof-of-Concept, Placebo-Controlled Studies of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder

Thomas Spencer, John H. Heiligenstein, Joseph Biederman et al. · The Journal of Clinical Psychiatry · 2002 · 336 citations

, , +17

Relapse Prevention in Pediatric Patients With ADHD Treated With Atomoxetine: A Randomized, Double-Blind, Placebo-Controlled Study

David Michelson, Jan K. Buitelaar, Marina Danckaerts et al. · Journal of the American Academy of Child & Adolescent Psychiatry · 2004 · 308 citations

, , +17

Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment

Víctor Pérez, Inmaculada Gilaberte, Douglas E. Faries et al. · The Lancet · 1997 · 299 citations

, , +14

1–5 of 96